Samantha Hopper

Background: Osteoporosis (OP) is a progressive skeletal disorder defined by a reduction in bone mineral density (BMD), diagnosed by a T-score ≤-2.5 via dual-energy x-ray absorptiometry.¹ This decline in BMD stems from a disruption in the balance between osteoblast-mediated bone formation and osteoclast-driven resorption, a process often influenced by underlying hormonal or metabolic imbalances that alter cellular function.¹’⁴ This compromises trabecular architecture and increases fracture susceptibility.¹’⁴ Healthcare costs related to OP are set to surpass more than $25 billion in 2025.² Current therapeutic strategies—including calcium and vitamin D supplementation, hormone replacement therapy, bisphosphonates, and monoclonal antibodies like denosumab—primarily aim to slow disease progression but fail to reverse bone loss and are often associated with significant adverse effects.¹ Moreover, diagnosis frequently occurs after substantial skeletal deterioration, further limiting treatment efficacy.¹ The rising prevalence of OP, driven by aging demographics and comorbidities such as obesity, diabetes, metabolic syndrome, and sedentary lifestyles, underscores the urgent need for novel, disease-modifying therapies.³ Collectively with late diagnosis and limitations of treatment options new alternatives with less side effects and increased efficacy especially in disease reversal are necessary.¹’ ³’ ⁴

Objective: This review critically examines the emerging therapeutic potential of induced pluripotent stem cells (iPSCs) and adipogenic pathway inhibitors, both as standalone interventions and in synergistic combination, to promote osteogenic differentiation and facilitate the regeneration of bone mass in osteoporotic patients.

Methods: A comprehensive literature search was conducted using PubMed and Google Scholar, focusing on publications from 2017 to 2025. Search terms included “osteoporosis,” “mesenchymal stem cells,” “induced pluripotent stem cells,” “adipogenic pathways inhibitors” and “Peroxisome Proliferator Activated Receptor Gamma.” Studies were selected based on relevance to the hypothesis and quality of evidence regarding osteogenic differentiation and bone regeneration.

Results: In osteoporotic patients, mesenchymal stem cells (MSCs) are markedly decreased in abundance and display a diminished potential for differentiation into both adipogenic and osteogenic pathways as compared to age matched healthy participants.⁵ The neoandrographolide derived from Andrographis paniculata plant demonstrated the ability to inhibit osteoclastogenesis and reduce inflammatory bone loss without cytotoxicity.⁶ iPSCs not only exhibit enhanced proliferative and multilineage differentiation potential on their own, but when combined with adipogenic pathway inhibitors, they synergistically amplify osteogenic differentiation—demonstrating significantly greater efficacy in promoting bone regeneration than either approach alone.⁷ Notably, the combined application of iPSCs and adipogenic pathway inhibitors enhances osteogenic commitment more effectively than either approach alone, suggesting a synergistic mechanism that may overcome the intrinsic limitations of MSCs in osteoporotic microenvironments.⁷’ ⁸

Conclusion: While adipogenic pathway inhibition via agents like Neoandrographolides presents a promising alternative to conventional therapies, its efficacy in reversing established osteoporosis remains limited due to the compromised regenerative capacity of endogenous MSCs. The integration of iPSC-based regenerative strategies with targeted inhibition of adipogenic signaling represents a novel and potentially transformative approach to not only halt but reverse osteoporotic bone loss. Further preclinical and clinical investigations are warranted to validate these findings and optimize therapeutic protocols for translational application.

Works Cited:

1. Lin H, Sohn J, Shen H, Langhans MT, Tuan RS. Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing. Biomaterials. 2019;203:96-110. doi:10.1016/j.biomaterials.2018.06.026
2. Singer A, McClung MR, Tran O, et al. Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis. Arch Osteoporos. 2023;18(1):42. Published 2023 Mar 11. doi:10.1007/s11657-023-01229-7
3. Wang X, Zhang C, Zhao G, Yang K, Tao L. Obesity and lipid metabolism in the development of osteoporosis (Review). International Journal of Molecular Medicine. 2024;54(1). doi:https://doi.org/10.3892/ijmm.2024.5385
4. ‌Qadir A, Liang S, Wu Z, Chen Z, Hu L, Qian A. Senile Osteoporosis: The Involvement of Differentiation and Senescence of Bone Marrow Stromal Cells. Int J Mol Sci. 2020;21(1):349. Published 2020 Jan 5. doi:10.3390/ijms21010349
5. Cassidy FC, Shortiss C, Thompson K, Arroquia AS, Murphy CG, Kearns SR, et al. Mesenchymal stromal cells from people with osteoporosis are fewer, and defective in both osteogenic and adipogenic capacity. Explor Musculoskeletal Dis. 2024;2:164–80. https://doi.org/10.37349/emd.2024.00046
6. Tang K, Deng W, Huang Z, Chen S, Zhu Z, Lin S, Zhong L, Zheng Q, Zhao W, Zhang Z, Mo L. Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis. Front Pharmacol. 2025;16:1466057. doi:10.3389/fphar.2025.1466057
7. Umrath F, Frick SL, Wendt V, Naros A, Zimmerer R, Alexander D. Inhibition of TGF-β signaling enhances osteogenic potential of iPSC-derived MSCs. Sci Rep. 2025;15(1):7814. doi:10.1038/s41598-025-89370-w.
8. Zhou M, Xi J, Cheng Y, Sun D, Shu P, Chi S, et al. Reprogrammed mesenchymal stem cells derived from iPSCs promote bone repair in steroid-associated osteonecrosis of the femoral head. Stem Cell Res Ther. 2021;12:175. doi:10.1186/s13287-021-02249-1.